Results from a single-institution study indicated that patients with melanomas of 4 mm thickness or greater who had negative sentinel lymph node biopsy (SLNB) had significantly prolonged survival compared with patients with positive SLNB.
MRV Research
Ipilimumab Plus Dacarbazine Provide Survival Benefit in Advanced Melanoma
According to a study published online last week in the Journal of Clinical Oncology, ipilimumab plus dacarbazine provide a durable survival benefit at 5 years in patients treated for advanced melanoma.
MD Anderson Studies Melanoma Patients Resistant To Therapy
Researchers from The University of Texas MD Anderson Cancer Center may have found a way to accurately predict which patients will be more likely to respond to genomic-based follow-up therapies by interpreting unique “protein patterns” in melanoma patients.
FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma
he FDA has accepted a supplemental Biologics License Application (sBLA) for ipilimumab (Yervoy) as an adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection, according to Bristol-Myers Squibb, the company developing the drug. The FDA is scheduled to make a decision on adjuvant ipilimumab by October 28, 2015.